Kala Pharmaceuticals Reports Third Quarter 2018 Financial Results 


INVELTYSTM Launch on Track for Early 2019 KPI-121 0.25% NDA Filed for Dry Eye Disease
“We have made substantial progress over the past few months. In addition to receiving U.S. Food (NDA) for KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease and extended our cash runway to include upcoming key milestones”, said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals.
“We remain focused on preparing for commercialization and building our sales force in anticipation of the INVELTYS launch in early 2019″…

[Read on via official release]

Source: US SEC
View full document: